Demand for the drugs is unlikely to slow down in 2024, especially as treatments gradually become more accessible. Much of Wall Street believes the weight loss drug market will only expand, with some analysts projecting that it will be worth $100 billion by the end of the decade. Goldman Sachs analysts expect 15 million U.S. adults … Read more
The U.S. Food and Drug Administration is expected to approve exa-cel gene-editing treatment for sickle cell disease. Exa-cel would be the first approved medicine in the U.S. to use CRISPR gene-editing technology. Vertex Pharmaceuticals and CRISPR Therapeutics co-developed the treatment, which could cost around $2 million per patient. At age 19, Joe Tsogbe underwent his … Read more
Blockbuster weight loss and diabetes drugs like Wegovy and Ozempic may be associated with an increased risk of three rare, but severe, stomach conditions in non-diabetic patients, according to a new study released Thursday. Researchers at the University of British Columbia said the risks include one condition not named in the warning labels for the … Read more
Scientists have begun investigating whether so-called miracle obesity drugs can be used to help treat conditions such as dementia and alcohol addiction. Recent trials have pointed to the drugs’ efficacy in curbing major cardiovascular events and reducing heart-failure related symptoms. The findings mark a milestone as pharmaceutical companies such as Novo Nordisk and Eli Lilly … Read more
My top 10 things to watch Wednesday 1. Equities are lower in premarket trading Wednesday, with the S & P 500 and Nasdaq Composite both down around 0.2%. Meanwhile, oil prices pulled back slightly after having soared 1.5% on Tuesday on the back of Saudi Arabia’s extended production cuts. West Texas Intermediate crude was trading … Read more
Novo Nordisk’s obesity drug Wegovy slashed the risk of serious heart problems by 20% in a large clinical trial. That landmark finding could put more pressure on U.S. insurers to cover the blockbuster medication and similar weight loss treatments. But organizations representing insurers emphasized that the data is still preliminary, and concerns remain about the … Read more
Popular weight-loss drug Wegovy could be made available under more health insurance schemes following the results of a late-stage trial, analysts said Wednesday. Novo Nordisk’s closely watched “SELECT” trial exceeded expectations Tuesday, indicating that Wegovy reduced the risk of major cardiovascular events such as heart attacks or strokes by 20%. “Data like this is going … Read more